Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH‐Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report
Case Reports in Neurological Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crnm/5250404 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Neurological Medicine, online erschienen am 30.07.2026. Verfasst von Carolina Pusec und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Wisconsin Madison, Madison, Wisconsin, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Central nervous system (CNS) World Health Organization (WHO) Grade 2 isocitrate dehydrogenase (IDH)‐mutant astrocytomas are classified as low‐grade gliomas with typically slow growth for many years followed by eventual malignant transformation and death. Here, we present a case of a patient with an IDH‐mutant Grade 2 astrocytoma who developed early radiographic tumor progression per Response Assessment in Neuro‐Oncology (RANO) 2.0 as evidenced by new enhancement on MRI T1 postcontrast 4 months after initiation of an IDH inhibitor. Subsequent re‐resection, one month later (or five months postinitiation of ivosidenib treatment), of the enhancing signal retained the Grade 2 designation without any histological or molecular progression per CNS WHO 2021 criteria. Specifically, the Ki‐67 proliferative index remained stable at approximately 2%, and copy number alterations were largely unchanged, including no CDKN2A/B homozygous deletion and relatively low chromosome copy number complexity. On histological examination, there was no elevation in mitotic activity and no features of necrosis or microvascular proliferation to suggest a more aggressive phenotype. The tumor demonstrated increased gemistocytic morphology and rare foci of foamy macrophages, as compared to prior. Following the second resection, the patient received sequential radiation therapy and adjuvant temozolomide chemotherapy treatment and has remained clinically stable on observation with surveillance MRIs for over 18 months. This case highlights the importance of re‐resection in IDH‐mutant gliomas, identifies the potential limitations of the response assessment criteria to differentiate treatment effect from true tumor progression, and emphasizes the need for ongoing investigation into novel genetic alterations, molecular signatures, and histologic markers to more accurately predict radiographic tumor behavior and guide more personalized, targeted treatment strategies for patients with IDH‐mutant gliomas.
Autor:innen und Institutionen
- Department of Neurology, University of Wisconsin Madison, Madison, Wisconsin, USA.
- Department of Pathology and Laboratory Medicine, University of Wisconsin Madison, Madison, Wisconsin, USA, lhsc.on.ca.
- Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA, uwm.edu.
- SSM Health Neurosciences, SSM Health St. Mary's Hospital, Madison, Wisconsin, USA, ssmhealth.com.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA, mskcc.org.
ORCID-Profile: Carolina Pusec, Karam Han, Krithi Gopinath, Michelle Mackay, Ankush Bhatia
Zitieren
APA
Pusec, C., Han, K., Gopinath, K., Mackay, M., Lozier, A., Bale, T. A., & Bhatia, A. (2026). Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH‐Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report. Case Reports in Neurological Medicine, 2026(1). https://doi.org/10.1155/crnm/5250404
Vancouver
Pusec C, Han K, Gopinath K, Mackay M, Lozier A, Bale TA, et al. Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH‐Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report. Case Reports in Neurological Medicine. 2026;2026(1). doi:10.1155/crnm/5250404
BibTeX
@article{Pusec2026,
author = {Pusec, Carolina and Han, Karam and Gopinath, Krithi and Mackay, Michelle and Lozier, Alan and Bale, Tejus A and Bhatia, Ankush},
title = {Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH‐Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report},
journal = {Case Reports in Neurological Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crnm/5250404}
}
EUVIMED